Drug delivery systems and formulations for treatment of metastatic melanoma (cancer)

Summary

 

Technology Description

 

A nanocarrier drug delivery platform that provides a pharmaceutical composition configured for selective uptake by lymph nodes and dissemination throughout the lymphatic system such that administration of the composition provides therapeutic efficacy at lymph nodes both proximal and distal to the site of administration. A three-drug loaded version of the nanocarrier vehicle was successfully tested for safety and efficacy in two transgenic metastatic melanoma models.

 

Features & Benefits

 

  • Achieves therapeutic concentration in the lymphatic system for improved therapeutic outcomes

 

Applications

 

  • Metastatic melanoma
  • Delivery of drugs to lymphatic system

 

Background of Invention

 

Metastatic melanoma has a high mortality rate due to lymphatic progression of the disease. Current treatment for late stage metastatic melanoma is surgery followed by radiation and intravenous chemotherapy; however, drawbacks for current chemotherapeutics lie in the fact that they develop resistance and do not achieve therapeutic concentrations in the lymphatic system.

 

 

Status

 

Patent pending; available for exclusive licensing

 

Patent Information:
Tech ID:
OSU-15-31
Category(s):
Therapeutics
Contact:
Joe Christison
IP & Licensing Manager
Oregon State University
541-737-9016
joe.christison@oregonstate.edu
Inventors:
Adam (Wathah) Alani
Keywords:
Pharmaceuticals
Drug
Drug Delivery
drugs
Therapeutic
Cancer
© 2017. All Rights Reserved. Powered by Inteum